Mariko Sugawara-Mikami, Kazunari Tanigawa, Akira Kawashima, Mitsuo Kiriya, Yasuhiro Nakamura, Yoko Fujiwara, Koichi Suzuki
8 min
Leprosy, caused by Mycobacterium leprae and M. lepromatosis, remains a significant global health challenge, with over 200,000 new cases reported annually. Although multidrug therapy has successfully reduced prevalence, the disease persists due to complex host-pathogen interactions and the bacterium's unique biological constraints. This paper provides an extensive review of the bacteriology, immunology, epidemiology, and pathogenesis of leprosy, emphasizing the molecular mechanisms that allow M. leprae to persist as an obligate intracellular pathogen.
The most striking feature of M. leprae is its extreme genome reduction. With nearly half of its genome comprised of pseudogenes and non-coding regions, the pathogen has lost the metabolic flexibility of its relative, M. tuberculosis. It is incapable of performing many independent anabolic processes and instead hijacks host cell machinery. Specifically, M. leprae manipulates host lipid metabolism—such as the synthesis of triacylglycerols and the accumulation of cholesterol—to support the maintenance of its complex cell wall and to survive long-term within immune-privileged niches. This dependence helps explain the pathogen’s incredibly slow generation time and the difficulty in culturing it outside of host cells.
M. leprae preferentially infects dermal macrophages and Schwann cells in the peripheral nerves. Within these cells, the bacterium modulates the host immune response to evade surveillance. For example, by inducing the formation of lipid droplets and activating peroxisome proliferator-activated receptors (PPARs), the pathogen creates an intracellular environment conducive to its own persistence. Nerve damage, a hallmark of leprosy, is mediated both by direct bacterial interaction with Schwann cell receptors like alpha-dystroglycan and by the host's inflammatory responses, such as those seen in leprosy reactions.
By delineating the mechanisms through which M. leprae relies on host-derived lipids and reprogrammed host cellular pathways, this review highlights potential new therapeutic targets. Standard antimicrobial treatments can successfully kill the bacteria, but they do not always address the underlying immune-mediated nerve damage or the potential for drug resistance. Future strategies focusing on disrupting the metabolic crosstalk between the pathogen and the host could be crucial to achieving the WHO’s goal of zero leprosy.
Leprosy is caused by Mycobacterium leprae (M. leprae) and M. lepromatosis, an obligate intracellular organism, and over 200,000 new cases occur every year. M. leprae parasitizes histiocytes (skin macrophages) and Schwann cells in the peripheral nerves. Although leprosy can be treated by multidrug therapy, some patients relapse or have a prolonged clinical course and/or experience leprosy reaction. These varying outcomes depend on host factors such as immune responses against bacterial components that determine a range of symptoms. To understand these host responses, knowledge of the mechanisms by which M. leprae parasitizes host cells is important. This article describes the characteristics of leprosy through bacteriology, genetics, epidemiology, immunology, animal models, routes of infection, and clinical findings. It also discusses recent diagnostic methods, treatment, and measures according to the World Health Organization (WHO), including prevention. Recently, the antibacterial activities of anti-hyperlipidaemia agents against other pathogens, such as M. tuberculosis and Staphylococcus aureus have been investigated. Our laboratory has been focused on the metabolism of lipids which constitute the cell wall of M. leprae. Our findings may be useful for the development of future treatments.
Alex: Are those lipids just debris from damaged cells, or is there evidence of active manipulation?
Sam: The review describes changes on both sides of fat storage: increased synthesis and reduced breakdown. In a human immune-cell line called THP-1, the authors identified triacylglycerol, a form of stored fat, as the major accumulated lipid. With live bacteria, accumulation persisted; with dead bacteria, it was temporary.
Alex: That comparison suggests live infection sustains the change. What happens if researchers interrupt the host’s fat-making machinery?
Sam: One enzyme, called GPAT3, helps make stored fat. Infection increased its expression. When researchers deleted its gene using CRISPR, infected THP-1 cells showed dramatically reduced fat accumulation compared with infected cells without that deletion.
Alex: That establishes a role in fat accumulation. Does it also show that removing the fat kills the bacteria?
Sam: Not from that result alone. The excerpt does not report a bacterial-survival result for that deletion. A separate experiment targeted cholesterol production: lovastatin reduced bacterial survival in infected primary macrophages. These findings support a link between host lipid metabolism and survival, but they don’t establish a treatment for patients.
Alex: How much weight should we put on those experiments if we want to design a follow-up study?
Sam: They provide a mechanistic starting point, not a clinical effect estimate. The excerpt gives neither sample counts nor numerical effect sizes for those highlighted experiments. Patient skin biopsies also show bacteria-containing compartments alongside lipid droplets, but that observation alone cannot establish what the bacteria use the fat for.
Alex: So the evidence joins tissue observations to experimental changes in cells. Where does the proposed chain still have a missing link?
Sam: The bacterial wall contains specialised fats, including mycolic acids, which help protect the organism. The authors propose that host fat stores may supply material for those wall components. But they explicitly say further work must establish whether leprosy bacteria actually make mycolic acid from host-derived stored fat.
Alex: That keeps the treatment idea narrower than “starve the bacterium.” There’s evidence of dependence, but the precise supply route remains unresolved.
Sam: And testing it is difficult. The bacterium takes roughly two weeks to complete a generation and is difficult to grow in ordinary culture media. Animal models each capture only parts of the disease. Armadillos can develop extensive nerve involvement, but laboratory breeding is a limitation.
Alex: Let’s connect intracellular survival to disability. Is nerve injury simply the result of bacteria multiplying inside nerve-supporting cells?
Sam: The review describes several routes, not just direct invasion. Bacterial components can make infected macrophages produce nitric oxide, a molecule that can contribute to nerve damage. Other pathways alter Schwann-cell signalling and strip away myelin, the insulating sheath around nerve fibres. Immune cells can also damage Schwann cells.
Alex: That creates a difficult balance: the host needs an effective response, but an excessive response can damage the tissue it should protect.
Sam: The clinical spectrum reflects that balance. At one end, strong cell-mediated immunity helps control bacteria in localised lesions. At the other, patients can produce abundant antibodies yet fail to control bacterial growth in widespread lesions. Antibody quantity is not equivalent to effective bacterial clearance here.
Alex: And antimicrobial treatment doesn’t necessarily switch those damaging responses off. How common are the reactions the review describes?
Sam: It reports leprosy reactions in roughly thirty to fifty percent of patients. These are sudden, severe immune responses to bacterial components, often appearing with antibiotic therapy. They are a major source of persistent nerve damage, deformity, and disability.
Alex: So a reaction is not automatically evidence that antibiotics failed. The infection and the inflammatory injury need separate attention.
Sam: Yes. The review distinguishes inflammation of existing lesions and nerves from another reaction involving painful skin lesions and systemic inflammation. It also discusses relapse and drug resistance as separate treatment challenges. Those are different problems, even when they complicate the same clinical course.
Alex: Where does that leave the established approach while researchers investigate host metabolism?
Sam: Multidrug therapy remains the recommended antimicrobial approach, using rifampicin, dapsone, and clofazimine. The review also covers early detection, resistance testing, and preventive treatment for contacts. Lipid-targeted drugs are a research direction alongside those measures, not a demonstrated replacement.
Alex: Who should read the full review, and where should they begin?
Sam: Researchers studying intracellular infection or host-directed treatments should start with “Lipid accumulation in infected cells.” Look closely at the live-versus-dead bacterial comparison and the fat-synthesis gene deletion. Keep the cholesterol-survival experiment separate: it tests a different intervention and outcome.
Alex: And for someone whose main concern is nerve injury rather than bacterial metabolism?
Sam: Start with “Role of Schwann cells in nerve injury,” then “Leprosy reaction.” Together they explain why bacterial control and protection from disability are not the same endpoint. For everyone else, remember this: treating the infection does not necessarily end the injury.
Alex: Thanks for listening.